P latelet disruption has been shown to release the powerful vasoconstrictor substances, 5 -hydroxytryptamine (5-HT) and thromboxane A2 (TXA2).l Both of these substances are candidates for the mediation of vasospasm since they are found in increased concentrations at the site of coronary arterial stenosis in animal models of vasospasm2'3 and in patients with acute coronary syndromes.4,5 Furthermore, it has been shown that the response to intracoronary injection of 5-HT is converted from a mild dilatation in healthy coronary arteries to a vasoconstriction in patients with atherosclerosis,6,7 but the receptor subtypes mediating this response have not been adequately characterized. Recent in vivo and in vitro studies suggest a possible role for 5-HT1-like and 5-HT2 receptors in mediating 5-HT-induced constriction in patients with ischemic heart disease. [8] [9] [10] The concentration of 5-HT and TXA2 that confronts ing platelets may rely on the action of either 5-HT or TXA2 alone or an interaction between the two. Such an interaction of coreleased substances may be mediated through receptor "cross-talk," resulting in additive or synergistic effects. A synergistic action of 5-HT and TXA2 has been demonstrated in the induction of cyclic flow variations in coronary flow in dog coronary arteries in vivo. 11 The aim of this study was to investigate whether such amplifying interactions between 5 -HT and TXA2 receptors may occur in human coronary arteries and to assess the role of the different subtypes of 5 -HT receptor in the interaction between these two vasoconstrictors. Methods A total of 168 vessel segments of epicardial coronary arteries were removed from 20 patients (mean age, 27 years) at the time of cardiac transplantation. These patients had been diagnosed as having angiographically normal coronary arteries and were undergoing transplantation for conditions other than ischemic heart disease (i.e., cardiomyopathy, congenital heart defects, lung disorders). These arteries showed no signs of atheroma on gross examination or under a dissecting microscope. This was confirmed in a selection of segments via histological examination. Arteries were placed immediately in a modified Tyrode's solution of Once a stable baseline tension had been achieved after the second KC1 depolarization, tissues were ex- posed to an EC10, EC30, or ECQ0 concentration of U46619. These concentrations were allowed to develop their maximum tension; once a plateau had been attained, increasing concentrations of 5-HT were added to the baths in 1/2og10lo units, while the U46619 was still present. Additions of 5-HT were made until the maximum response of 5 -HT had been reached. Some vessel segments received no U46619 before the addition of 5-HT and acted as controls.
In a second series of experiments, vessel segments were incubated with the 5-HT2 receptor antagonist ketanserin (10-6 M) for 1 (Figure 1) . The Figure 2 ). The maximum effect achieved by 5-HT in these tissues (after subtraction of the U46619 effect) decreased in the order EC30>control>EC0O>EC50 (Table 1 ). However, the maximum effect of 5--HT at any level of U46619-induced tone was not statistically different from the control (no U46619). The presentation of the mean data masks important changes in the reactivity to 5-HT observed in some tissues. In artery segments from two patients, it was possible to see either an increase in potency and/or an increase in the maximum effect of 5--HT in the presence of the thromboxane mimetic. Representative traces and graphs from these patients are shown in Figure 3 . The induction of cyclic activity on induced constriction was common to segments that received the higher doses of U46619. Usually, 5--HT was still capable of inducing further increases in tension that was underlying this cyclic activity.
In a second series of experiments, the interaction between 5--HT (10-6 M) and U46619 was examined in the presence of ketanserin (10-6 M) Interactions between TXA2 and 5 -HT have previously been shown to enhance the activity of platelets and to augment their biological effects. The formation of TXA2 has also been shown to enhance the release of 5-HT from storage sites in the dense tubular system of platelets.12 Inhibition of platelet-induced cyclic flow variations in dogs has been shown to require a combination of both 5-HT2 receptor and TXA2 receptor antagonists. In a similar manner, the efficacy of thrombolysis is enhanced by simultaneous administration of TXA2 and 5 -HT2 receptor antagonists in a canine model. 13 The interaction between 5 -HT and U46619 has im- Platelet-induced vasoconstriction of isolated bovine coronary arteries has been shown to be due to two separate mechanisms.17 The first phase, which is rapid in onset and of short duration, is thought to be due to TXA2, whereas the second phase, which is slower in onset but long lasting, is mediated by 5 -HT. The data in the present study indicate that the magnitude of the 5-HT-mediated phase of platelet-induced vasoconstriction may be enhanced by the prior release of TXA2.
Our study has shown that none of the vessels preconstricted by U46619 showed any relaxation in response to 5-HT. The integrity of the endothelium in such segments is maintained, as reported in our previous studies. 18, 19 This confirms previous reports that human epicardial coronary arteries do not have a direct relaxant response to 20, 21 and that the small relaxation to 5-HT seen in vivo probably occurs via an indirect mechanism. 6, 7, 22 There is increasing evidence that platelet-derived 5-HT is involved in the mediation of vasospastic events.23 5 -HT has been shown to be present in increased concentrations in patients with limiting angina and coronary lesions.5 Furthermore, this amine has divergent effects in patients with atherosclerotic compared with healthy arteries. In vivo and in vitro studies have demonstrated that regions distal to atherosclerotic lesions, a region in which vasospasm usually occurs, have ketanserin-resistant 5-HT1-like receptors.8,10 These 5-HT1-like receptors mediated 50% of the total response of 5-HT in diseased arteries, whereas they were capable of inducing a contraction equal to 30% of the maximum achieved by 5-HT in healthy arteries. 8 The failure of ketanserin in the treatment of coronary vasospasm has cast doubt on the role of 5 -HT receptors in the mediation of vasospasm.24'25 However, this antagonist is ineffective at blocking the action of 5-HT at 5-HT1-like receptors. Our results show that 5-HTinduced constriction mediated by 5-HT1-like receptors can be augmented after activation of TXA2 receptors. The possibility exists that there are areas in diseased coronary arteries where the effect mediated by these receptors may be sufficient to cause coronary occlusion. Further studies are warranted that use more specific receptor probes. The use of the selective 5-HT1-like receptor agonists and the development of a specific antagonist at the 5-HT1-like receptor will permit clarification of the combined role of these receptors in coronary vasospasm in vivo.
